Peptomyc closes €5.7 million round as Catalonia's public bank ICF joins

The story so far, in brief; the legwork, and the full article, stay with the original outlet.

Peptomyc has finished raising its equity round, which now stands at €5.7 million. Most of that arrived in February, when a first close of €5 million was led by Alta Life Sciences Spain I F.C.R., a fund advised by Asabys Partners, and Aurora Science, with the EIC Fund, Laudecum and CDTI Innovación, through its SICC Innvierte, also taking part. The final €0.7 million comes from the Institut Català de Finances, the Generalitat de Catalunya's public promotion bank, and is the very first investment of its Lidera Transferència en Salut fund. That fund has €60 million, €50 million from the Generalitat and €10 million from the ICF, so the cap table now carries public money at the Catalan, Spanish and European level, which is a fairly complete set.

The money will go to finishing three clinical studies of OMO-103 already under way, getting manufacturing ready for later stages of development and moving forward talks with possible pharmaceutical partners. OMO-103 is described as the first direct pan-MYC inhibitor to succeed in the clinic, as published in Nature Medicine in 2024.

Since the first close, Peptomyc has named Dr Stephan Braun chief medical officer, and it plans to present phase 1b data for OMO-103 in first-line metastatic pancreatic cancer before the end of 2026.